- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04503096
Plasticity Using Stimulation and Habit: A Pilot Open-label rTMS Study for MCI (PUSH-Pilot)
September 1, 2023 updated by: Andreana Benitez, Medical University of South Carolina
High-dose Accelerated Repetitive Transcranial Magnetic Stimulation to Cognitive Control Neurocircuitry in Mild Cognitive Impairment: A Safety and Feasibility Study
The goal of this pilot study is to determine whether a high-dose form of non-invasive brain stimulation is a promising and safe treatment for Mild Cognitive Impairment (MCI).
Transcranial magnetic stimulation (TMS) is an FDA approved treatment for depression.
In studies of TMS for depression and other disorders, individuals have experienced improved cognitive function.
Thus, the current study is testing whether TMS is safe, feasible and effective in improving cognition in individuals with MCI.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years to 85 years (Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 60-85
- English as a first/primary language
- Has been diagnosed with MCI by a healthcare provider within the past two years per National Institute on Aging - Alzheimer's Association (NIA-AA) criteria: (1) Concern regarding cognitive decline reported by patient, informant, or clinician, (2) Objective evidence of impairment for age in 1+ cognitive domains, typically memory, (3) Preserved independent function, (4) no dementia.
- Has met actuarial neuropsychological criteria for amnestic MCI: (1) ≥2 impaired scores (i.e. ≤16th %ile) within one cognitive domain, or (2) ≥1 impaired scores (i.e. ≤16th %ile) in ≥3 cognitive domains, using demographically-corrected normative data. (1) and (2) must include the Memory domain.
- The primary suspected etiology of amnestic MCI must be neurodegenerative, with competing differential diagnoses (e.g. psychiatric disorder, movement disorder, reversible causes, substance use) ruled out as the primary etiology/ies following a clinical evaluation by a healthcare provider.
- Ability to provide independent informed consent, consistent with the MCI diagnostic criterion of preserved independent function.
Exclusion Criteria:
- Dementia diagnosis per the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) or NIA-AA criteria.
- Daily/weekly use of anticholinergics, neuroleptics, sedatives, or bupropion. Stimulant use may be allowed pending investigator review. Cholinesterase inhibitors, NMDA receptor antagonists, and antidepressants are allowed if on a stable regimen of four weeks prior to enrollment.
- History of significant or unstable condition/s that may impact cognition such as significant cardiac, cerebrovascular, or metabolic disease, severe mental illness (e.g. bipolar disorder, psychoses), alcohol or substance use disorder, developmental disorder, or other neurologic disease (e.g. severe brain injury, seizures).
- MRI and TMS contraindications (e.g., implants, claustrophobia, conditions/treatments that lower seizure threshold, taking medications that have short half-lives, no quantifiable motor threshold, active substance use disorder, bipolar disorder).
- Is enrolled in a clinical trial and/or has received an investigational medication within the last 30 days.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High-dose accelerated rTMS
|
A MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System will be utilized.
All participants will receive open-label treatment for approximately eight, 3-minute sessions of intermittent theta burst rTMS on each of three days within an eight-day span.
A single session = 600 pulses at 120% resting motor threshold (rMT), intermittent Theta Burst Stimulation (iTBS) triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 s to left dorsolateral prefrontal cortex.
Total pulses = 14,400.
To enable adherence and retention, the days do not need to be contiguous.
Same day sessions will be separated by 10-15 minutes, but more accounting for participant comfort.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Clinically Significant Structural Brain Change on T1- and T2-weighted Magnetic Resonance Imaging (MRI)
Time Frame: Baseline prior to treatment and at follow-up within 1 week post-treatment
|
Clinically significant structural brain change were determined by a board-certified neuroradiologist who reviewed both the pre-treatment and post-treatment structural (T1- and T2-weighted) MRI scans to identify the presence of any changes from pre- to post-treatment based on their clinical read of the images.
|
Baseline prior to treatment and at follow-up within 1 week post-treatment
|
Change From Baseline Global Cognition, as Measured by the Montreal Cognitive Assessment (MoCA)
Time Frame: Baseline prior to treatment and at follow-up within 1 week post-treatment
|
The MoCA is a psychometrist-administered brief cognitive assessment tool with raw total scores ranging from 0 to 30, with higher values indicating better cognition.
For this analysis raw total scores were converted to age- and education-adjusted Z-scores using published norms (Rossetti et al., 2011).
Z-scores have a mean of 0 and a standard deviation of 1. Lower scores indicate worse performance.
The outcome measure reported below is the mean Z-score score at the 1-week post-treatment assessment.
The statistical analysis compares this mean score to the mean score at Baseline.
|
Baseline prior to treatment and at follow-up within 1 week post-treatment
|
Change in the Review of Systems Criteria Compared to Baseline
Time Frame: Baseline prior to treatment and at follow-up within 1 week post-treatment
|
A review of systems questionnaire will be administered to rate the subjective symptom (headache, scalp pain, arm/hand pain, other pain(s), numbness/tingling, other sensation(s), weakness, loss of dexterity, vision/hearing change(s), ear ringing, nausea/vomiting, appetite loss, rash, skin change(s) or any other symptom(s)) on a scale of 0 to 5 (none, minimal, mild, moderate, marked, severe).
|
Baseline prior to treatment and at follow-up within 1 week post-treatment
|
Patient Perception of Treatment Acceptability
Time Frame: Administered at post-treatment
|
A 15-item study-specific questionnaire of rTMS treatment acceptability, with each item rated on a scale from 1 to 5 (1 = not at all, 3 = somewhat, 5 = very much so).
Higher scores indicate better acceptability for the first 10 items, lower scores indicate better acceptability for the last 5 items.
|
Administered at post-treatment
|
Retention Rate
Time Frame: Baseline prior to treatment and at follow-up within 1 week post-treatment
|
Percentage of participants who completed the study (n=21) relative to all participants who initiated treatment (n=22).
|
Baseline prior to treatment and at follow-up within 1 week post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline Depression, as Measured by the Hamilton Depression Rating Scale (HAM-D)
Time Frame: Baseline prior to treatment and at follow-up within 1 week post-treatment
|
The Hamilton Depression Rating Scale (Ham-D) is a 17-item interviewer-administered structured questionnaire designed to assess symptoms of depression with scores ranging from 0 to 53, with higher scores indicating more depressive symptoms.
The outcome measure reported below is the mean score at the 1-week post-treatment assessment.
The statistical analysis compares this mean score to the mean score at Baseline.
|
Baseline prior to treatment and at follow-up within 1 week post-treatment
|
Change From Baseline Depression, as Measured by the Geriatric Depression Scale (GDS)
Time Frame: Baseline prior to treatment and at follow-up within 1 week post-treatment
|
The Geriatric Depression Scale (GDS) is a 30-item scale that evaluates the severity of depressive symptoms in older adults with scores ranging from 0 to 30, with higher scores indicating more depressive symptoms.
The outcome measure reported below is the mean score at the 1-week post-treatment assessment.
The statistical analysis compares this mean score to the mean score at Baseline.
|
Baseline prior to treatment and at follow-up within 1 week post-treatment
|
Change From Baseline Cognition, as Measured by the Fluid Cognition Composite Score From the NIH Toolbox Cognition Battery
Time Frame: Baseline prior to treatment and at follow-up within 1 week post-treatment
|
Fluid cognition was measured using the iPad-administered NIH Toolbox Cognition Battery (NIHTB-CB).
Fluid Cognition Composite scores were calculated by averaging the demographically adjusted (age, education, sex, race/ethnicity; Casaletto et al., 2015) T-scores for 4 NIHTB-CB tests: the flanker inhibitory control, list sorting working memory, pattern comparison processing speed, and dimensional change card sort tests.
T-Scores have a mean of 50 and a standard deviation of 10.
Lower scores indicate worse performance.
The outcome measure reported below is the mean T-score at the 1-week post-treatment assessment.
The statistical analysis compares this mean score to the mean score at Baseline.
|
Baseline prior to treatment and at follow-up within 1 week post-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Lisa McTeague, PhD, Medical University of South Carolina
- Principal Investigator: Andreana Benitez, PhD, Medical University of South Carolina
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 12, 2021
Primary Completion (Actual)
June 29, 2022
Study Completion (Actual)
July 27, 2022
Study Registration Dates
First Submitted
August 3, 2020
First Submitted That Met QC Criteria
August 5, 2020
First Posted (Actual)
August 7, 2020
Study Record Updates
Last Update Posted (Actual)
September 7, 2023
Last Update Submitted That Met QC Criteria
September 1, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00100536
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
University of California, San FranciscoNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognitive Impairment, Mild | Cognitive Deficits, MildUnited States
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.RecruitingMild Cognitive Impairment (MCI)Taiwan
-
Thomas Jefferson UniversityJohns Hopkins University; University of Pennsylvania; National Institute on Aging... and other collaboratorsCompletedMild Cognitive Impairment (MCI)United States
-
Palo Alto Veterans Institute for ResearchU.S. Army Medical Research and Development CommandCompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Assaf-Harofeh Medical CenterNeurim Pharmaceuticals Ltd.UnknownMild Cognitive Impairment (MCI)Israel
-
Xuanwu Hospital, BeijingWuhan University; Beijing Friendship Hospital; First Affiliated Hospital Xi'an... and other collaboratorsRecruitingAmnestic Mild Cognitive ImpairmentChina
-
Immunotec Inc.RecruitingMild Cognitive Impairment (MCI)Canada
-
Jennifer BramenNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Meir Medical CenterTerminatedMild Cognitive Impairment (MCI)Israel
Clinical Trials on High-dose accelerated rTMS
-
Universitair Ziekenhuis BrusselWithdrawnDepression | Old Age
-
Berthold Langguth, MD, Ph.D.RecruitingAlcohol DependenceGermany
-
University of Texas at AustinNot yet recruitingDepression | Major Depressive Disorder | Treatment Resistant Depression | MDD | Recurrent DepressionUnited States
-
Douglas Mental Health University InstituteCompleted
-
Radboud University Medical CenterSanofiUnknownHead and Neck CancerNetherlands
-
University Hospital, GhentCompletedBreast Cancer | RadiotherapyBelgium
-
Texas Woman's UniversityTerminated
-
Xuanwu Hospital, BeijingCompleted
-
National University Hospital, SingaporeTan Tock Seng HospitalUnknownStage III Non-Small Cell Lung CancerSingapore
-
University of TehranStanford UniversityCompletedBipolar Depression | Major Depressive DisorderIran, Islamic Republic of